Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan

<!DOCTYPE html> <html lang="en"> <head><meta charset="utf-8" /><title> Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan </title><link href="../../../Content/Site.css" rel="stylesheet" /><link href="../../../Content/bootstrap-3.3.2-dist/css/bootstrap.min.css" rel="stylesheet" /><link href="../../../Content/bootstrap-3.3.2-dist/css/bootstrap.icon-large.min.css" rel="stylesheet" /><link href="//maxcdn.bootstrapcdn.com/font-awesome/4.3.0/css/font-awesome.min.css" rel="stylesheet" /><link href="../../../Content/Custom.css" rel="stylesheet" /><link href="../../../favicon.ico" rel="shortcut icon" type="image/x-icon" /> <script src="/Scripts/modernizr-2.5.3.js"></script> <meta name="viewport" content="width=device-width" /> <script type="text/javascript" src="https://www.jcnnewswire.com/jquery/jquery-latest.min.js"> </script> <script type="text/javascript" src="https://www.jcnnewswire.com/jquery/jquery.fancybox.pack.js?v=2.1.5"></script> <link rel="stylesheet" type="text/css" href="https://www.jcnnewswire.com/jquery/jquery.fancybox.css?v=2.1.5" media="screen"> <style> .lang li { display:inline; } .lang a { color:#fff; } </style> <script type="text/javascript"> (function(c,l,a,r,i,t,y){ c[a]=c[a]||function(){(c[a].q=c[a].q||[]).push(arguments)}; t=l.createElement(r);t.async=1;t.src="https://www.clarity.ms/tag/"+i; y=l.getElementsByTagName(r)[0];y.parentNode.insertBefore(t,y); })(window, document, "clarity", "script", "559ucihkaw"); </script> </head> <body> <form method="post" action="./Rozebalamin-for-Injection-25mg-(Mecobalamin)-for-Amyotrophic-Lateral-Sclerosis-Launched-in-Japan" onsubmit="javascript:return WebForm_OnSubmit();" id="ctl01"> <div class="aspNetHidden"> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="/wEPDwUKLTU1NzE2ODMwMmRkQm9CgPio/0fT/ZYOQDphR4Wwdl+U9CT/FL4ILUAwS9s=" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['ctl01']; if (!theForm) { theForm = document.ctl01; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="/WebResource.axd?d=YcG_1mlPARhRW7O4sA9bWHA-qI2d_t_BO06OeFBhoaiREhheyXs3-1psdTUSDOHCoQeBPKlq2r8vu_cSQNfig-Is-AxTXJhRKwfH8V2oM9c1&t=638611161180000000" type="text/javascript"></script> <script src="/WebResource.axd?d=bIpPyEdzAMer_bwfyhWa6rFaO8WGfxnN2PvV0BTsVTDvSo40Rw6pGSZlPV1TZTu152c0lKoeiKGVeRIzWI8ylmApYjdRpTU999mo98-2hDs1&t=638611161180000000" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ function WebForm_OnSubmit() { if (typeof(ValidatorOnSubmit) == "function" && ValidatorOnSubmit() == false) return false; return true; } //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="2173C2F0" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAAPY6V5cLF3bfaZTtYsjoFTJsK8Qcg6x7YEKBpnNUn26Cy8zACrOsmKsedR3ZCAsXqPGzqKkIBrU3/Ojevxn9ucX4+xldtAxhlj22lca6s+8/A==" /> </div> <header> <div style="background-color:#000;"> <div class="content-wrapper"> <div style="color:#fff;padding-bottom:22px;"> <span style="float:right;"> <ul class="lang"> <li style="font-size:12px;color:#ABA9A9;"> <a href="/english/"> ENGLISH</a> </li> <li style="font-size:12px;color:#ABA9A9;">|</li> <li style="font-size:12px;color:#ABA9A9;"><a href="/japanese/"> JAPANESE</a></li> <li style="font-size:12px;color:#ABA9A9;"> | </li> <li style="font-size:12px;color:#fff;"> CONNECT WITH US:</li> <li class="nolink"> <a href="https://www.facebook.com/jcnnewswire" target="_blank" class="social"> <i class="fa fa-facebook-square"></i></a> </li> <li class="nolink"> <a href="https://twitter.com/JCNNewswire" target="_blank" class="social"><i class="fa fa-twitter-square"></i></a> </li> <li class="nolink"> <a href="/rssfeed/" class="social"><i class="fa fa-rss-square"></i></a> </li> </ul> </span> </div> </div> </div> <br /> <div class="content-wrapper"> <div class="feature-float-left"> <p class="site-title"><a href="../../../"> <img src="/Images/JCN-Newswire.jpg" width="300px"/></a></p> </div> <div class="float-right"> <nav class="topnav"> <ul class="nav nav-tabs"> <li role="presentation"><a href="../../../">Home</a></li> <li role="presentation"><a href="../../../About/">About</a></li> <li role="presentation"><a href="../../../Contact/">Contact</a></li> <li role="presentation"><a href="../../../Client/" id="A1">Log in</a></li> <li style="padding-top:5px;"> <span id="RequiredFieldSearch" style="color:Red;visibility:hidden;">*</span> <input name="ctl00$searchstring" type="text" id="searchstring" placeholder="Search for..." style="width:150px;height:30px;font-size:14px;" /><input type="submit" name="ctl00$SearchButton" value="Go!" onclick="javascript:WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$SearchButton", "", true, "", "", false, false))" id="SearchButton" class="btn btn-default" type="submit" style="height:30px;font-size: 13px;margin-left:2px;background-color:#f2f2f2;border-color:#ccc;" /> </li> </ul> </nav> </div> </div> </header> <div id="body"> <section class="content-wrapper main-content clear-fix">  <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-54f7fe387839d451" async="async"></script> <ol class="breadcrumb"> <li><a href="/">Home</a></li> <li class="active">Press release</li> </ol> <table>  <tr valign="top"><td> <div class="col-lg-12 clearfix"> <table width="100%"> <tr> <td> <div id="MainContent_CompanyInfo"> <span id="MainContent_releaseDate" class="small">Nov 20, 2024 11:51 JST</span><br /> <span id="MainContent_companyLogo"><img src="http://www.jcnnewswire.com/image/company/eisai.240.jpg" class="companyLogo"></span><br /> <span id="MainContent_companySource" class="small">Source: <a href="http://www.eisai.com" target="_blank">Eisai</a></span> </div> </td> <td class="float-right"> <div class="addthis_sharing_toolbox"></div> </td> </tr> </table> </div> <p style="padding-bottom:100px;"></p> <div class="col-lg-9"> <table> <tr><td> <div align="justify" class="title"><span id="MainContent_HeadLine" class="header">Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan</span></div> <div align="justify"><strong></strong></div> <div align="justify"><span id="MainContent_Body" class="bodytext"><p><strong>TOKYO, Nov 20, 2024 - (JCN Newswire) - </strong>Eisai Co., Ltd. announced today that the amyotrophic lateral sclerosis (ALS) treatment “Rozebalamin® for Injection25 mg” (mecobalamin) has been launched in Japan as a treatment for slowing progression of functionalimpairment in amyotrophic lateral sclerosis. The product received manufacturing and marketing approval in Japan on September 24, 2024, and was published in Japan’s National Health Insurance Drug Price List today.<br><br><img style="display: block; margin-left: auto; margin-right: auto;" src="https://photos.acnnewswire.com/ASL.jpg" alt="" width="468" height="212"></p> <p>This approval is based on the results of JETALS (The Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS),multicenter, placebo-controlled, double-blind, randomized Phase III clinical trial in 130 patients with ALS, that was conducted as an investigator-initiated trial by a research team with Extraordinary Professor Ryuji Kaji (Principal Investigator), Tokushima University, and Professor Yuishin Izumi (Coordinating Investigator), the Department of Neurology,Tokushima University Graduate School of Biomedical Sciences, and Professor Satoshi Kuwabara (Coordinating Investigator), the Department of Neurology, Chiba University Graduate School of Medicine.1</p> <p>ALS is an intractable, progressive, neurodegenerative disease that results in severe muscle atrophy and weakness in the muscles due to motor neuron dysfunction. As the main cause of death is respiratory failure due to paralysis of the respiratory muscles, without the use of an artificial respirator, death occurs within approximately 2 to 5 years from the onset of the disease.2 The number of patients in Japan is estimated to be approximately10,000.2 Currently, there is no curative treatment established for ALS, and since there are only limited number of medicines approved in Japan and abroad, this is a disease with significant unmet medical needs.</p> <p>Eisai considers neurology a therapeutic area of focus. As a human healthcare company, Eisai is committed to further addressing the diverse needs of, and increasing the benefits of, patients and their families by providing Rozebalamin as a new treatment option for ALS patients.<br><br><strong>Product Outline</strong></p> <p>Product name: Rozebalamin® for Injection 25 mg Generic name: Mecobalamin<br>Indication for use: Slowing progression of functional impairment in amyotrophic lateral sclerosis<br>Dosage and administration: The usual dose of mecobalamin in adults is 50 mg a day, twice a week, injected intramuscularly.<br>National Health Insurance (NHI) Drug Price: Rozebalamin® for Injection 25 mg 1 vial 10,425 JPY Packaging: Rozebalamin® for Injection 25 mg 8 vials</p> <p><strong>About Rozebalamin (generic name: mecobalamin, development code: E0302)</strong></p> <p>Mecobalamin is approved and marketed as Methycobal®, a 500 µg injection of mecobalamin indicated for the treatmentof peripheral neuropathies and megaloblastic anemia caused by vitamin B12 deficiency. Methycobal is also approved as a tablet formulation (250 µg and 500 µg) as well as a fine granule formulation (0.1%) indicated for the treatment of peripheral neuropathies. While the mechanism of action of mecobalamin against amyotrophic lateral sclerosis (ALS) is not known, it has been suggested in non-clinical research that mecobalamin may have efficacy through a neuroprotective effect and regeneration of nerve axons. Since the 1990s, clinical research has been carried out by a study group on the Ministry of Health, Labour and Welfare, suggested that ultrahigh-dose mecobalamin, which is respectively 50 and 100 times the approved dosage of Methycobal, could have a clinical effect in ALS, and Eisai then conducted the Phase II/III clinical trial (Study 761) from 2006. Eisai submitted a new drug application in May 2015 but the Pharmaceuticals and Medical Devices Agency (PMDA) indicated that additional clinical trials were necessary.</p> <p>After obtaining favorable results in the investigator-initiated Phase III trial JETALS, and following consultation withTokushima University, Eisai submitted a new drug application for the treatment of ALS in Japan in January 2024, leading to its approval in September, 2024 and leading to the launch today. In May 2022, Rozebalamin received orphan drug designation from the Japanese Ministry of Health, Labour and Welfare.</p> <p><strong>About Japan Early-stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS)</strong></p> <p>The Japan Early-stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) is an investigator-initiated study conducted as a multicenter, placebo-controlled, double-blind, randomized Phase III clinical trial to verify the efficacy and safety of high-dose methylcobalamin (mecobalamin) in patients with amyotrophic lateral sclerosis (ALS).1</p> <p>Mecobalamin 50 mg or placebo was administered intramuscularly twice weekly for 16 weeks to 130 ALS patients who had suffered from ALS for less than one year, were classified as “definite”, “probable”, or “probable- laboratory supported” according to the Updated Awaji Criteria, had an ALS severity rating of grade 1 or 2, had a decrease of 1 or 2 points inthe total score on the Revised ALS Functional Rating Scale-Revised (ALSFRS-R) 12 weeks prior to administration, and had a forced vital capacity (%FVC) of more than 60%.3</p> <p>The primary endpoint was the change in ALSFRS-R total score from the end of the observation period to week 16 of the treatment period. The change was -2.7 [95% confidence interval (CI): -3.9, -1.5] in the mecobalamin</p> <p>50 mg group and -4.6 [95% CI: -5.8, -3.4] in the placebo group, with a difference in change of 2.0 (95% CI: 0.4, 3.5; p=0.012), verifying the superiority of mecobalamin 50 mg over placebo.3 The adverse drug reaction incidence rate was 1.6% (1/64 cases) in the placebo group and 7.7% (5/65 cases) in the mecobalamin 50 mg group. Adverse drugreactions observed in the mecobalamin 50 mg group were constipation, injection site pain, fever, electrocardiogram QT prolongation, and rash, occurring in 1.5% (1/65 cases) each.3</p> <p>(1) Oki R, et al. Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral sclerosis a randomized clinical trial. JAMA Neurol. 2022;79(6):575-583.<br>(2) Japan Intractable Diseases Information Center, Amyotrophic lateral sclerosis (ALS), Designated intractable disease (2). <a href="https://www.nanbyou.or.jp/entry/52">https://www.nanbyou.or.jp/entry/52.</a> Last accessed: September 2024. (Japanese only)<br>(3) Information stated in the package insert.<br><br><strong>Media Inquiries:<br></strong>Public Relations Department, Eisai Co., Ltd.<br>+81-(0)3-3817-5120</p></span></div> <div align="justify"><span id="MainContent_CompanyName" class="bodytext"></span></div> <div align="justify"><span id="MainContent_CompanyBoiler" class="bodytext"></span></div> <div align="justify"><span id="MainContent_Contact" class="bodytext"></span></div> <div align="justify"><span id="MainContent_Source" class="note">Source: Eisai<BR />Sectors: Healthcare & Pharm <BR /><BR /></span></div> <div align="justify"><span id="MainContent_Copyright" class="bodytext"><p>Copyright 漏2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.<p></span></div> </td></tr> </table> <hr /> <h3><span id="MainContent_Label1">Latest Release</span></h3> <span id="MainContent_LatestRelease_LatestPressRelease"><table width="100%" cellpadding=0 cellspacing=0><tr><td class="articleDate"><img title="TOPVISION Eye Specialist Bhd" src="http://www.jcnnewswire.com/image/toppage/TOPVISION68.jpg"><br /><a href="/pressrelease/94103/3/TOPVISION-Launches-Prospectus-for-Listing-Transfer-from-LEAP-to-the-ACE-Market" class="newslink">TOPVISION Launches Prospectus for Listing Transfer from LEAP to the ACE Market</a><br /><span class="note"> Nov 27, 2024 05:53 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Toyota Motor Corporation" src="http://www.jcnnewswire.com/image/toppage/ToyotaBb.68.jpg"><br /><a href="/pressrelease/94092/3/TOYOTA-GAZOO-Racing-FULLY-PREPARED-FOR-DAKAR-2025" class="newslink">TOYOTA GAZOO Racing FULLY PREPARED FOR DAKAR 2025</a><br /><span class="note"> Nov 26, 2024 17:55 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Eisai" src="http://www.jcnnewswire.com/image/toppage/eisai45.jpg"><br /><a href="/pressrelease/94087/3/Eisai-Signs-Research-Collaboration-Agreement-with-The-National-Center-of-Neurology-and-Psychiatry-to" class="newslink">Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan</a><br /><span class="note"> Nov 26, 2024 15:50 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Fujitsu Ltd" src="http://www.jcnnewswire.com/image/toppage/Fujitsu.Logo.68.jpg"><br /><a href="/pressrelease/94079/3/Fujitsu-develops-Policy-Twin,-a-new-digital-twin-technology-to-maximize-effectiveness-of-local-gover" class="newslink">Fujitsu develops Policy Twin, a new digital twin technology to maximize effectiveness of local government policies for solving societal issues</a><br /><span class="note"> Nov 26, 2024 10:51 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Toyota Motor Corporation" src="http://www.jcnnewswire.com/image/toppage/ToyotaBb.68.jpg"><br /><a href="/pressrelease/94072/3/TOYOTA-GAZOO-Racing-reinforces-WRC-line-up-with-youth-and-experience-for-2025" class="newslink">TOYOTA GAZOO Racing reinforces WRC line-up with youth and experience for 2025</a><br /><span class="note"> Nov 25, 2024 17:10 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Toyota Motor Corporation" src="http://www.jcnnewswire.com/image/toppage/ToyotaBb.68.jpg"><br /><a href="/pressrelease/94068/3/Toyota-Submits-Progress-Report-on-Recurrence-Prevention-Measures" class="newslink">Toyota Submits Progress Report on Recurrence Prevention Measures</a><br /><span class="note"> Nov 25, 2024 15:43 JST</span><br /></td></tr><tr><td class="articleDate"><img title="TOPVISION Eye Specialist Bhd" src="http://www.jcnnewswire.com/image/toppage/TOPVISION68.jpg"><br /><a href="/pressrelease/94065/3/TOPVISION-Launches-Prospectus-for-Transfer-Listing-from-LEAP-to-the-ACE-Market" class="newslink">TOPVISION Launches Prospectus for Transfer Listing from LEAP to the ACE Market</a><br /><span class="note"> Nov 25, 2024 15:00 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Heavy Industries, Ltd." src="http://www.jcnnewswire.com/image/toppage/MHI_newT.jpg"><br /><a href="/pressrelease/94064/3/MHI-Thermal-Systems-Receives-Order-from-Aisan-Industry-for-Aquifer-Thermal-Energy-Storage-System-for" class="newslink">MHI Thermal Systems Receives Order from Aisan Industry for Aquifer Thermal Energy Storage System for Its New Anjo Plant</a><br /><span class="note"> Nov 25, 2024 14:18 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Honda Motor Co, Ltd" src="http://www.jcnnewswire.com/image/toppage/honda.gif"><br /><a href="/pressrelease/94060/3/Oracle-Red-Bull-Racing-Driver-Max-Verstappen-Wins-Fourth-Consecutive-F1-Drivers-World-Championship" class="newslink">Oracle Red Bull Racing Driver Max Verstappen Wins Fourth Consecutive F1 Drivers' World Championship</a><br /><span class="note"> Nov 25, 2024 11:55 JST</span><br /></td></tr><tr><td class="articleDate"><br /><a href="/pressrelease/94045/3/Kaplan-Fox-&-Kilsheimer-LLP-Alerts-Investors-to-a-Securities-Class-Action-Against-Humacyte,-Inc-(HUM" class="newslink">Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025</a><br /><span class="note"> Nov 22, 2024 11:00 JST</span><br /></td></tr><tr><td class="articleDate"><img title="NaaS Technology Inc." src="http://www.jcnnewswire.com/image/toppage/NAAS64.jpg"><br /><a href="/pressrelease/94025/3/NaaS-Q3-2024-Recap:-Strategic-Shifts-and-Tech-Innovations-for-Growth" class="newslink">NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth</a><br /><span class="note"> Nov 21, 2024 22:59 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Honda Motor Co, Ltd" src="http://www.jcnnewswire.com/image/toppage/honda.gif"><br /><a href="/pressrelease/94013/3/Honda-Unveils-Demonstration-Production-Line-for-All-Solid-State-Batteries-Located-in-Sakura-City,-To" class="newslink">Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan</a><br /><span class="note"> Nov 21, 2024 15:35 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Kaplan Fox & Kilsheimer LLP" src="http://www.jcnnewswire.com/image/toppage/Kaplan-Fox-Logo-Small.jpg"><br /><a href="/pressrelease/94009/3/Deadline-to-Lead-in-Securities-Fraud-Lawsuit-Against-Humacyte,-Inc-(HUMA)-is-January-17,-2025---Cont" class="newslink">Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP</a><br /><span class="note"> Nov 21, 2024 09:00 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Lexaria Bioscience" src="http://www.jcnnewswire.com/image/toppage/Lexaria.55.jpg"><br /><a href="/pressrelease/93991/3/ALL-Study-Groups-Using-DehydraTECH-Processing-Outperform-Rybelsus(R)-in-Body-Weight-Control-in-Lexar" class="newslink">ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study</a><br /><span class="note"> Nov 20, 2024 23:05 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Heavy Industries, Ltd." src="http://www.jcnnewswire.com/image/toppage/MHI_newT.jpg"><br /><a href="/pressrelease/93993/3/Start-of-Demonstration-Test-of-Two-Phase-Direct-to-Chip-Cooling-in-the-Air-Cooled-Data-Center" class="newslink">Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center</a><br /><span class="note"> Nov 20, 2024 15:30 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Eisai" src="http://www.jcnnewswire.com/image/toppage/eisai45.jpg"><br /><a href="/pressrelease/93992/3/Rozebalamin-for-Injection-25mg-(Mecobalamin)-for-Amyotrophic-Lateral-Sclerosis-Launched-in-Japan" class="newslink">Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan</a><br /><span class="note"> Nov 20, 2024 11:51 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Eisai" src="http://www.jcnnewswire.com/image/toppage/eisai45.jpg"><br /><a href="/pressrelease/93990/3/Anticancer-Agent-TASFYGO-Tablets-35mg-(Tasurgratinib-Succinate)-Launches-in-Japan-for-Biliary-Tract-" class="newslink">Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements</a><br /><span class="note"> Nov 20, 2024 10:24 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Kingsoft Corporation Limited" src="http://www.jcnnewswire.com/image/toppage/kingsoft.gif"><br /><a href="/pressrelease/93971/3/Kingsoft-Announces-2024-Third-Quarter-Results" class="newslink">Kingsoft Announces 2024 Third Quarter Results</a><br /><span class="note"> Nov 19, 2024 18:54 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Olympus" src="http://www.jcnnewswire.com/image/toppage/olympus-68.jpg"><br /><a href="/pressrelease/93934/3/NTT-and-Olympus-Joint-Demonstration-Shows-IOWN-APNs-Low-latency-Capability-Can-Be-Used-for-Real-time" class="newslink">NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System</a><br /><span class="note"> Nov 19, 2024 15:30 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Fujitsu Ltd" src="http://www.jcnnewswire.com/image/toppage/Fujitsu.Logo.68.jpg"><br /><a href="/pressrelease/93955/3/Supercomputer-Fugaku-retains-first-place-worldwide-in-HPCG-and-Graph500-rankings" class="newslink">Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings</a><br /><span class="note"> Nov 19, 2024 09:02 JST</span><br /></td></tr></table></span> <a id="MainContent_LatestRelease_MoreRelease" href="/MoreNews_j/3">More Latest Release >></a> </div> <div class="col-lg-3"> <span id="MainContent_RelatedNews_RelatedNews"><div class="sidebar-module-inset"><h4>Related Release</h4><table width="100%" cellpadding=0 cellspacing=0><tr><td><a href="/pressrelease/94087/3/Eisai-Signs-Research-Collaboration-Agreement-with-The-National-Center-of-Neurology-and-Psychiatry-to">Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan</a></td></tr><tr><td class="note">11/26/2024 3:50:00 PM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93990/3/Anticancer-Agent-&quotTASFYGO-Tablets-35mg&quot-(Tasurgratinib-Succinate)-Launches-in-Japan-for-Bili">Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements</a></td></tr><tr><td class="note">11/20/2024 10:24:00 AM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93908/3/Nationwide-TV-Commercial-Launched-in-Japan-to-Raise-Awareness-About-MCI-(Mild-Cognitive-Impairment)">Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)</a></td></tr><tr><td class="note">11/15/2024 5:33:00 PM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93902/3/Eisai-Receives-Positive-Opinion-from-the-CHMP-in-the-European-Union-for-Lecanemab-in-Early-Alzheimer">Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease</a></td></tr><tr><td class="note">11/15/2024 2:31:00 PM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93674/3/Eisai&aposs-Corporate-Venture-Capital-Subsidiary,-Eisai-Innovation,-Inc,-Selected-for-AMED&aposs-&ap">Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"</a></td></tr><tr><td class="note">11/5/2024 11:35:00 AM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93641/3/Eisai-Completes-Rolling-Submission-to-US-FDA-for-LEQEMBI(R)-(lecanemab-irmb)-Biologics-License-Appli">Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status</a></td></tr><tr><td class="note">11/1/2024 1:56:00 PM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93626/3/Eisai-Presents-Data-on-Benefits-of-Long-Term-Administration-of-Dual-Acting-Lecanemab-at-the-17th-Cli">Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference</a></td></tr><tr><td class="note">10/31/2024 1:56:00 PM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93621/3/Eisai-Presents-Latest-Clinical-Findings-Suggesting-Inhibition-of-Tau-Propagation-by-Anti-MTBR-Tau-An">Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)</a></td></tr><tr><td class="note">10/31/2024 11:33:00 AM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93364/3/A-Joint-Regional-Cohort-Study-by-Shimadzu,-Eisai,-Oita-University,-and-Usuki-City-Medical-Associatio">A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association</a></td></tr><tr><td class="note">10/17/2024 8:01:00 PM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93360/3/Update-on-Regulatory-Review-of-Lecanemab-for-Early-Alzheimer&aposs-Disease-in-Australia">Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia</a></td></tr><tr><td class="note">10/17/2024 3:59:00 PM JST</td></tr><tr><td> </td></tr><tr><td align="center"><a href="/CompanyNews/93992/3">More Press release >></a></td></tr></table></dl></div></span> </div> </td></tr> </table> <script type="text/javascript"> $(document).ready(function () { $("#single_1").fancybox({ helpers: { title: { type: 'float' } } }); }); </script> </section> </div> <footer> <div class="content-wrapper"> <div align="center"> Copyright © 2024 - JCN Newswire <div class="botton-nav"> <ul> <li><a href="../../../">Home</a></li> <li><a href="../../../About/">About</a></li> <li><a href="../../../Contact/">Contact</a></li> <li><a href="../../../RssFeed/">RSS</a></li> <li><a href="../../../Cookies/">Cookies Policy</a></li> <li><a href="../../../Disclaimer/">Disclaimer</a></li> <li><a href="../../../Privacy/">Privacy Policy</a></li> <li><a href="../../../Terms/">Terms of Use</a></li> <li> - </li> <li> Connect with us:</li> <li class="nolink"> <a href="https://www.facebook.com/jcnnewswire" target="_blank" class="social"> <i class="fa fa-facebook-square"></i></a> </li> <li class="nolink"> <a href="https://twitter.com/JCNNewswire" target="_blank" class="social"><i class="fa fa-twitter-square"></i></a> </li> <li class="nolink"> <a href="/rssfeed.aspx" class="social"><i class="fa fa-rss-square"></i></a> </li> </ul> </div> </div> </div> </footer> <script type="text/javascript"> //<![CDATA[ var Page_Validators = new Array(document.getElementById("RequiredFieldSearch")); //]]> </script> <script type="text/javascript"> //<![CDATA[ var RequiredFieldSearch = document.all ? document.all["RequiredFieldSearch"] : document.getElementById("RequiredFieldSearch"); RequiredFieldSearch.controltovalidate = "searchstring"; RequiredFieldSearch.errormessage = "*"; RequiredFieldSearch.evaluationfunction = "RequiredFieldValidatorEvaluateIsValid"; RequiredFieldSearch.initialvalue = ""; //]]> </script> <script type="text/javascript"> //<![CDATA[ var Page_ValidationActive = false; if (typeof(ValidatorOnLoad) == "function") { ValidatorOnLoad(); } function ValidatorOnSubmit() { if (Page_ValidationActive) { return ValidatorCommonOnSubmit(); } else { return true; } } //]]> </script> </form> <script> (function (i, s, o, g, r, a, m) i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () (i[r].q = i[r].q || []).push(arguments) }, i[r].l = 1 * new Date(); a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g; m.parentNode.insertBefore(a, m) })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga'); ga('create', 'UA-61831624-1', 'auto'); ga('send', 'pageview'); </script> </body> </html>

CINXE.COM

Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan